TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23793945
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of furosemide (10 mg/h)
Study: 23793945
Drug: Bolus of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of furosemide (20 mg/6 h)
Study: 23793945
Drug: Bolus of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bolus of furosemide (20 mg/8 h)
Study: 21494186
Drug: Probiotic fermented
Normalized name: Rezyst Probiotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotic fermented milk administered 3 times daily for 8 weeks
Study: 21494186
Drug: Placebo administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered 3 times daily for 8 weeks
Study: 12610049
Drug: 1.25 mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.25 mg/day ramipril
Study: 16186399
Drug: 5 mg/day
Normalized name: Lyllana 0.05 MG/Day Transdermal Patch
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 mg/day ramipril
Study: 9890408
Drug: Amlodipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine (5 mg/day for first 4 weeks, then 10 mg/day for second 4 weeks)
Study: 27702624
Drug: 2.0 mg
Normalized name: LORAZEPAM 2.0 mg in 1 mL INTRAVENOUS INJECTION
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.0 mg intravitreal aflibercept injections (IAIs)
Study: 24052800
Drug: Cognitive stimulation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive stimulation treatment
Study: 24052800
Drug: Occupational therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Occupational therapy (placebo)
Study: 21263308
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (10% Travasol)
Study: 15039148
Drug: Dexamethasone (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dexamethasone (2 mg orally every 6 h for 3 days)
Study: 15039148
Drug: Amino acid
Normalized name: Amino Acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amino acid infusion (10% Travasol) with dexamethasone
Study: 11511425
Drug: NPR‐C receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPR‐C receptor density in patients with HF (class III‐IV)
Study: 11511425
Drug: NPR‐C receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPR‐C receptor density in patients with HF (class I‐II)
Study: 11511425
Drug: NPR‐C receptor
Approvals — FDA: no, EMA: no, PMDA: no
Description: NPR‐C receptor density in healthy controls
Study: 11511425
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of NPR‐C receptor density between class III‐IV HF patients and controls
Study: 11511425
Drug: Comparison of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Comparison of NPR‐C receptor density between class III‐IV HF patients and class I‐II HF patients
Study: 29135656
Drug: 3-monthly creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3-monthly creatinine clearance (CrCl) monitoring
Study: 29135656
Drug: 6-monthly creatinine
Normalized name: Creatinine
DrugBank: Creatinine (DB11846)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-monthly creatinine clearance (CrCl) monitoring
Study: 24251386
Drug: Functionally orientated
Normalized name: Papaver orientale seed oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Functionally orientated treatment based on the shortened dental arch concept (SDA)
Study: 18711405
Drug: CABG with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: CABG with intramuscular or intracoronary administration of BMCs
Study: 15866056
Drug: Nondiabetic control
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nondiabetic control (no insulin)
Study: 2223423
Drug: CsA concentrations
Normalized name: CsA
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CsA concentrations measured by h.p.l.c.
Study: 31957070
Drug: 2 g
Normalized name: Molds 2 g
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 g amoxicillin pre-operative and 500 mg thrice daily on days 1-3 post-operative
Study: 30824647
Drug: Adalimumab 40
Normalized name: ADALIMUMAB 40MG/0.8ML INJ,PEN,KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adalimumab 40 mg once every 2 weeks
Study: 30824647
Drug: Baseline CRP
Approvals — FDA: no, EMA: no, PMDA: no
Description: Baseline CRP levels > 2.87 mg/l
Study: 28067745
Drug: Trospium chloride
Normalized name: Trospium Chloride
DrugBank: Trospium (DB00209)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Trospium chloride XR 60 mg daily
Study: 22185811
Drug: mpHBV (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: mpHBV (10 µg HBsAg)
Study: 22185811
Drug: RECOMBIVAX HB™
Approvals — FDA: no, EMA: no, PMDA: no
Description: RECOMBIVAX HB™ (10 µg HBsAg)
Study: 22185811
Drug: ENGERIX‐B™ (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: ENGERIX‐B™ (20 µg HBsAg)
Study: 18940221
Drug: Encepur Children
Normalized name: Pediaclear Childrens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Encepur Children (third dose)
Study: 17075252
Drug: 0.025% levocabastine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.025% levocabastine hydrochloride ophthalmic suspension
Study: 2454372
Drug: Carvedilol (12.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Carvedilol (12.5 to 200 mg)
Study: 3312502
Drug: Propranolol (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propranolol (40 to 320 mg)
Study: 2454372
Drug: Pindolol (2.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pindolol (2.5 to 20 mg)
Study: 2454372
Drug: Labetalol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Labetalol (50 to 400 mg)
Study: 29423840
Drug: LED therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: LED therapy (λ627 ± 10 nm) with an energy density of 10 J/cm2 for 6 days
Study: 29423840
Drug: Placebo therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo therapy (LED therapy turned off) for 6 days
Study: 23225211
Drug: Lycopene-enriched virgin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lycopene-enriched virgin olive oil (7 mg lycopene day(‐1))
Study: 18274695
Drug: Transdermal estradiol
Normalized name: estradiol Transdermal System
DrugBank: Estradiol (DB00783)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Transdermal estradiol (0.1 mg/d)
Study: 3602014
Drug: Pentoxifylline ('Trental'
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentoxifylline ('Trental' 400) 400 mg 3-times daily for two 3-month periods interrupted by a 4-week wash-out period
Study: 18313028
Drug: Glutamate injection
Normalized name: glutamate
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Glutamate injection into the masseter muscle
Study: 11725598
Drug: Shuttle walking
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Shuttle walking test with various orthopaedic treatments
Study: 25311594
Drug: Traditional voice
Normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Traditional voice therapy
Study: 11758004
Drug: Chlamydia pneumoniae
Normalized name: Chlamydia pneumoniae Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in CAD patients with CRF
Study: 11758004
Drug: Chlamydia pneumoniae
Normalized name: Chlamydia pneumoniae Ab
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chlamydia pneumoniae infection (measured by IgG and IgA antibodies) in all CAD patients
Study: 11758004
Drug: Mean antibody
Normalized name: digoxin antibodies Fab fragments Injection [DigiFab]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mean antibody index of IgG in CAD patients
Study: 11758004
Drug: Elevated IgG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated IgG antibody index
Study: 7951567
Drug: Euglycemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NGT subjects (n = 13)
Study: 7951567
Drug: Euglycemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in BGI subjects (n = 12)
Study: 7951567
Drug: Euglycemic insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Euglycemic insulin clamp technique achieving hyperinsulinemia (50‐70 microU/ml) in NIDDM subjects (n = 12)
Study: 12074223
Drug: Slow flow
Normalized name: Slow Sodium
Approvals — FDA: no, EMA: no, PMDA: no
Description: Slow flow rate (161 sec/mL) of 0.3 mL local anesthetic solution
Study: 12074223
Drug: Fast flow
Normalized name: Fast Freeze
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fast flow rate (29 sec/mL) of 0.3 mL local anesthetic solution
Study: 8083715
Drug: Front-loading consolidation
Normalized name: Bos taurus frontal lobe preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Front-loading consolidation therapy (6 MTX/Ara-C infusions at 3-week intervals from 7th to 19th week)
Study: 8083715
Drug: Standard consolidation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard consolidation therapy (6 MTX/Ara-C infusions every 12 weeks from 7th to 67th week)
Study: 22304627
Drug: 250 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 250 μg of r-hCG
Study: 22304627
Drug: 500 μg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 μg of r-hCG
Study: 18756184
Drug: Concomitant use
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concomitant use of oral pentavalent rotavirus vaccine (PRV) and oral poliovirus vaccine (OPV)
Study: 1371633
Drug: Diazepam 5
Normalized name: diazepam 5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diazepam 5 mg p.o.
Study: 1371633
Drug: Atropine 0.01
Normalized name: atropine 0.0194 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.01 mg/kg i.m.
Study: 29332637
Drug: Disorder-oriented multicomponent
Normalized name: Oriental melon
DrugBank: Muskmelon (DB15611)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disorder-oriented multicomponent group therapy (12 sessions of 90 minutes each) integrating interactive psychoeducation, gut-directed hypnotherapy, and open group phases.
Study: 20410466
Drug: Therapy-based oncology
Approvals — FDA: no, EMA: no, PMDA: no
Description: Therapy-based oncology RCTs
Study: 11575897
Drug: Terbutaline (Bricanyl
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (Bricanyl Turbuhaler 0.5 mg)
Study: 9272401
Drug: Yohimbine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Yohimbine (3 x 6 mg per day)
Study: 9272401
Drug: Anetholtrithione (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anetholtrithione (3 x 25 mg per day)
Study: 7942085
Drug: Hormone Replacement
Normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Hormone Replacement Therapy (HRT) with estradiol and estradiol plus medroxyprogesterone acetate
Study: 3367488
Drug: HPV‐77 DE‐5
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐77 DE‐5 rubella virus vaccine
Study: 3367488
Drug: HPV‐77 DK‐12
Approvals — FDA: no, EMA: no, PMDA: no
Description: HPV‐77 DK‐12 rubella virus vaccine
Study: 56908
Drug: Epontol (7
Approvals — FDA: no, EMA: no, PMDA: no
Description: Epontol (7 mg/kg i.v.)
Study: 56908
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection of Epontol (7 mg/kg) and infusion (21 mg/kg during 15 min)
Study: 56908
Drug: Combined injection
Normalized name: combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined injection of Epontol (7 mg/kg) and suxamethonium (0.5 mg/kg)
Study: 31893588
Drug: Control (traditional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (traditional balanced salt solution-infused technique)
Study: 25365122
Drug: Minimal-treatment home
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Minimal-treatment home study control condition
Study: 23057434
Drug: Milk (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk (5 mL)
Study: 23057434
Drug: Glucose (25%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose (25% glucose water, 5 mL)
Study: 23057434
Drug: Water (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water (5 mL distilled water)
Study: 21665265
Drug: Heparin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Heparin plus a glycoprotein IIb/IIIa inhibitor (GPI)
Study: 16912354
Drug: Subcutaneous extralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous extralesional triamcinolone acetonide injection (0.3 mL, 10 mg/mL)
Study: 16912354
Drug: Conservative treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conservative treatment (lid hygiene, warm compresses, chloramphenicol 1% ointment 4 times a day)
Study: 16912354
Drug: Subcutaneous extralesional
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous extralesional triamcinolone acetonide injection
Study: 14755153
Drug: Probiotics in
Normalized name: Niacinamide 1.00 g in 50 mL / Adenosine 0.02 g in 50 mL TOPICAL LIQUID [Ambling Plant Probiotics Into Nature Essence I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probiotics in capsules
Study: 11985972
Drug: Prophylaxis group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylaxis group (2 g of cephtazidime intravenously 30 minutes before ERCP)
Study: 9271042
Drug: DTPa-IPV vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV vaccine
Study: 9271042
Drug: DTPa-IPV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV and Hib vaccine (mixed)
Study: 9271042
Drug: DTPa-IPV and
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPa-IPV and Hib vaccine (separate)
Study: 9271042
Drug: DTPw-IPV-Hib vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: DTPw-IPV-Hib vaccine
Study: 3366075
Drug: Intravenous fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoterol (bolus injection and continuous infusion)
Study: 3366075
Drug: Intravenous fenoterol
Normalized name: fenoterol
DrugBank: Fenoterol (DB01288)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fenoterol
Study: 3366075
Drug: Simultaneous and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simultaneous and continuous intravenous administration of fenoterol and theophylline
Study: 25053749
Drug: FroDex25 (frovatriptan
Approvals — FDA: no, EMA: no, PMDA: no
Description: FroDex25 (frovatriptan 2.5 mg + dexketoprofen 25 mg)
Study: 21447908
Drug: Supervised exercise
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised exercise training program twice a week for 6 weeks
Study: 15381675
Drug: L-NAME (66
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-NAME (66 microg/kg per min for 30 minutes)
Study: 15381675
Drug: L-arginine (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (3 g TID) plus ramipril (10 mg QD)
Study: 11528242
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 40 mg of iron during the first ten HD sessions (n = 12)
Study: 11528242
Drug: Weekly injection
Normalized name: elagolix
DrugBank: Elagolix (DB11979)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Weekly injection of 40 mg of iron for 10 weeks (n = 12)
Study: 9623154
Drug: Inhalation of
Normalized name: Ocean brand of sodium chloride Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhalation of sodium cromoglycate through a spacer device
Study: 7940732
Drug: OKT3-based immunoprophylaxis
Approvals — FDA: no, EMA: no, PMDA: no
Description: OKT3-based immunoprophylaxis with steroids and azathioprine for 14 days, cyclosporine introduced on day 11 posttransplant.
Study: 7940732
Drug: Cyclosporine-based immunoprophylaxis
Normalized name: Cyclosporine
DrugBank: Cyclosporine (DB00091)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclosporine-based immunoprophylaxis with steroids and azathioprine.
Study: 3349748
Drug: Procan SR
Normalized name: Procan SR
DrugBank: Procainamide (DB01035)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Procan SR 1 g
Study: 3349748
Drug: Pronestyl-SR 1
Normalized name: procainamide hydrochloride Oral Tablet [Pronestyl]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pronestyl-SR 1 g
Study: 25743733
Drug: Oral care
Normalized name: Oral Care Q4 Kit KIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral care with an aroma solution
Study: 19288431
Drug: Intensity of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensity of therapy increased from 3 to 5 hours
Study: 17217710
Drug: Olmesartan medoxomil
Normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Olmesartan medoxomil 20 mg
Study: 15565999
Drug: BID group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: BID group (0.5 g morning and evening)
Study: 15565999
Drug: TID group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: TID group (0.25 g in the morning and about midday, and 0.5 g in the evening)
Study: 1389661
Drug: iohexol with
Normalized name: Iohexol
DrugBank: Iohexol (DB01362)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: iohexol with NaCl (28 mmol/l)
Study: 30098162
Drug: Medical or
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Medical or surgical treatment of the study eye (SE)
Study: 23736314
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg oral naltrexone (NTX)
Study: 23736314
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg oral naltrexone (NTX)
Study: 23736314
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg oral naltrexone (NTX)
Study: 23736314
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg oral D-amphetamine (D-AMPH)
Study: 23736314
Drug: 20 mg
Normalized name: urea 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20 mg oral D-amphetamine (D-AMPH)
Study: 23736314
Drug: 0 mg
Normalized name: RNA 180 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0 mg smoked cocaine (COC)
Study: 23736314
Drug: 12.5 mg
Normalized name: rutin 12.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 12.5 mg smoked cocaine (COC)
Study: 23736314
Drug: 25 mg
Normalized name: talc 25 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25 mg smoked cocaine (COC)
Study: 23736314
Drug: 50 mg
Normalized name: talc 50 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg smoked cocaine (COC)
Study: 21871685
Drug: Intensive insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intensive insulin treatment (Group A)
Study: 21871685
Drug: Conventional insulin
Normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Conventional insulin treatment (Group B)
Study: 17098309
Drug: Intravenous boluses
Normalized name: phenylbutazone
DrugBank: Phenylbutazone (DB00812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous boluses of quinaprilat
Study: 17098309
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of sodium nitroprusside
Study: 11578760
Drug: D002 (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: D002 (50 mg/day)
Study: 1859509
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of 60 mg amitriptylinoxide
Study: 1859509
Drug: Oral administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral administration of 60 mg amitriptylinoxide
Study: 1859509
Drug: Overall tolerability
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall tolerability of both preparations
Study: 24225379
Drug: Fluocortolone (FC)
Normalized name: fluocortolone
DrugBank: Fluocortolone (DB08971)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluocortolone (FC) 1 mg/kg for 5 days, followed by stepwise dose reduction
Study: 21952668
Drug: MDMA 0
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 0 mg (placebo)
Study: 21952668
Drug: MDMA 25
Normalized name: MDMA
DrugBank: Midomafetamine (DB01454)
Approvals — FDA: no, EMA: no, PMDA: no
Description: MDMA 25 mg
Study: 3140150
Drug: Veralipride (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Veralipride (100 mg/day for 30 days)
Study: 3140150
Drug: Naloxone infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone infusion (N = 5) after Veralipride administration
Study: 29893223
Drug: Personalised hip
Normalized name: HIP
DrugBank: Heme iron polypeptide (DB11067)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised hip therapy
Study: 28814431
Drug: Calprotectin after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calprotectin after 12 months of treatment
Study: 20569725
Drug: Vernakalant (3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vernakalant (3 mg/kg intravenous infusion for 10 minutes, followed by 2 mg/kg if needed)
Study: 17996926
Drug: Cyclophosphamide‐doxorubicin‐cisplatin (CAP)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide‐doxorubicin‐cisplatin (CAP) chemotherapy
Study: 4054701
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg tds with meals
Study: 4054701
Drug: Cimetidine 600
Normalized name: cimetidine 600 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 600 mg at bedtime
Study: 4054701
Drug: Cimetidine 200
Normalized name: cimetidine 200 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cimetidine 200 mg tds with meals plus 400 mg at bedtime
Study: 30114193
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of antibiotics
Study: 30114193
Drug: Symptoms influence
Normalized name: Pamprin Multi-Symptom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symptoms influence on antibiotic use
Study: 30114193
Drug: Income influence
Normalized name: Lincomed
Approvals — FDA: no, EMA: no, PMDA: no
Description: Income influence on antibiotic receipt
Study: 30114193
Drug: Determinants of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Determinants of antibiotic use
Study: 1963130
Drug: Rate of
Normalized name: Citrate of Magnesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rate of patient enrollment in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Study: 1963130
Drug: Inactive patients
Normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inactive patients in the Early Treatment Diabetic Retinopathy Study (ETDRS)
Study: 27650328
Drug: Montelukast (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Montelukast (20 mg/day)